ReviewExpert opinion on drug discovery2013
Advances in MRSA drug discovery: where are we and where do we need to be?
Review in Expert opinion on drug discovery, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 60 citations in OpenAlex.
- α-Mangostin Competing the Menaquinone-Binding Sites of NDH-2 to Block the Electron Transfer at the Quinone Pool ofAntibiotics (Basel, Switzerland) · 2026Article
- Darunavir: A Versatile Protease Inhibitor against Microbial Infections.Current drug discovery technologies · 2025Review
- Article
- A Novel Antimicrobial Mechanism of Azalomycin F Acting on Lipoteichoic Acid Synthase and Cell Envelope.Molecules (Basel, Switzerland) · 2024Article
- Treatment of MRSA Infection: Where are We?Current medicinal chemistry · 2024Review
- A Review on Five and Six-Membered Heterocyclic Compounds Targeting the Penicillin-Binding Protein 2 (PBP2A) of Methicillin-ResistantMolecules (Basel, Switzerland) · 2023Review
- Quinone Pool, a Key Target of Plant Flavonoids Inhibiting Gram-Positive Bacteria.Molecules (Basel, Switzerland) · 2023Article
- Antimicrobial Quantitative Relationship and Mechanism of Plant Flavonoids to Gram-Positive Bacteria.Pharmaceuticals (Basel, Switzerland) · 2022Article
- Bayesian Modeling and Intrabacterial Drug Metabolism Applied to Drug-ResistantACS infectious diseases · 2021Article
- Antibacterial activity and mechanism of plant flavonoids to gram-positive bacteria predicted from their lipophilicities.Scientific reports · 2021Article
- Design and Synthesis of Small Molecules as PotentAntibiotics (Basel, Switzerland) · 2020Review
- Inhibitor design to target a unique feature in the folate pocket of Staphylococcus aureus dihydrofolate reductase.European journal of medicinal chemistry · 2020Article
- Biologically active marine natural products and their molecular targets discovered using a chemical genetics approach.Natural product reports · 2020Review
- BPEI-Induced Delocalization of PBP4 Potentiates β-Lactams against MRSA.Biochemistry · 2019Article
- Exit tunnel modulation as resistance mechanism of S. aureus erythromycin resistant mutant.Scientific reports · 2019Article
- New Tetramic Acids Comprising of Decalin and Pyridones FromFrontiers in microbiology · 2019Article
- Discovery of Furanoquinone Derivatives as a Novel Class of DNA Polymerase and Gyrase Inhibitors for MRSA Eradication in Cutaneous Infection.Frontiers in microbiology · 2019Article
- A Computer-Driven Approach to Discover Natural Product Leads for Methicillin-ResistantMarine drugs · 2018Article
- Strategies to Encapsulate theViruses · 2018Article
- Synergistic combination of two antimicrobial agents closing each other's mutant selection windows to prevent antimicrobial resistance.Scientific reports · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
introductionMethicillin-resistant Staphylococcus aureus (MRSA) have been on the increase during the past decade, due to the steady growth of the elderly and immunocompromised patients, and the emergence of multidrug-resistant (MDR) bacterial strains. Although there are a limited number of anti-MRSA drugs available, a number of different combination antimicrobial drug regimens have been used to treat serious MRSA infections. Thus, the addition of several new antistaphylococcal drugs into clinical practice should broaden clinician's therapeutic options. As MRSA is one of the most common and problematic bacteria associated with increasing antimicrobial resistance, continuous efforts for the discovery of lead compounds as well as development of alternative therapies and faster diagnostics are required. AREAS COVERED: This article summarizes the FDA-approved drugs to treat MRSA infections, the drugs in clinical trials, and the drug leads for MRSA and related Gram-positive bacterial infections. In addition, the article discusses the mode of action of antistaphylococcal molecules and the resistant mechanisms of some molecules. EXPERT OPINION: The number of pipeline drugs presently undergoing clinical trials is not particularly encouraging. There are limited and rather expensive therapeutic options for MRSA infections in the critically ill. Further research efforts are required for effective phage therapy on MRSA infections in clinical use, which seem to be attractive therapeutic options for the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.